Plus Therapeutics (NASDAQ:PSTV) Trading Down 3.5%

Plus Therapeutics, Inc. (NASDAQ:PSTV) shares dropped 3.5% during mid-day trading on Tuesday . The company traded as low as $1.83 and last traded at $1.93. Approximately 69,150 shares changed hands during trading, an increase of 25% from the average daily volume of 55,479 shares. The stock had previously closed at $2.00.

Plus Therapeutics Stock Down 3.6 %

The firm has a 50 day moving average price of $2.03 and a 200 day moving average price of $1.97. The stock has a market cap of $10.60 million, a PE ratio of -0.63 and a beta of 0.58.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Wednesday, May 15th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.34. Plus Therapeutics had a negative net margin of 193.49% and a negative return on equity of 805.57%. The business had revenue of $1.68 million for the quarter. During the same period last year, the business posted ($2.10) EPS.

Insider Activity at Plus Therapeutics

In related news, CEO Marc H. Hedrick purchased 12,255 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average cost of $2.04 per share, for a total transaction of $25,000.20. Following the acquisition, the chief executive officer now owns 12,425 shares of the company’s stock, valued at approximately $25,347. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 26,961 shares of company stock valued at $55,000 over the last ninety days. 2.32% of the stock is owned by company insiders.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.